ALK alterations and inhibition in lung cancer

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

The advent of precision medicine in non-small cell lung cancer has remarkably altered the direction of research and improved clinical outcomes. The identification of molecular subsets with differential response to targeted therapies began with the identification of epidermal growth factor receptor mutated tumors in subsets of non-small cell lung cancer (NSCLC). Emboldened by unprecedented response rates to kinase inhibitors seen in that subset, the oncologic community searched for other molecular subsets featuring oncogene addiction. An early result of this search was the discovery of NSCLC driven by activating rearrangements of the anaplastic lymphoma kinase (ALK) gene. In an astoundingly brief period following the recognition of ALK-positive NSCLC, details of the biology, clinicopathologic features, development of targeted inhibitors, mechanisms of therapeutic resistance, and new generations of treatment were elucidated. This review summarizes the current understanding of the pathologic features, diagnostic approach, treatment options, resistance mechanisms, and future research areas for ALK-positive NSCLC.

Original languageEnglish (US)
Pages (from-to)81-88
Number of pages8
JournalSeminars in Cancer Biology
Volume42
DOIs
StatePublished - Feb 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Precision Medicine
Therapeutics
Oncogenes
Epidermal Growth Factor Receptor
Phosphotransferases
anaplastic lymphoma kinase
Research
Genes
Neoplasms

Keywords

  • Adenocarcinoma
  • Crizotinib
  • Oncogene addiction
  • Personalized medicine
  • Precision medicine
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

ALK alterations and inhibition in lung cancer. / Le, Tri; Gerber, David E.

In: Seminars in Cancer Biology, Vol. 42, 01.02.2017, p. 81-88.

Research output: Contribution to journalReview article

@article{4df7653d41ed4da2abdd26bfd07a3a33,
title = "ALK alterations and inhibition in lung cancer",
abstract = "The advent of precision medicine in non-small cell lung cancer has remarkably altered the direction of research and improved clinical outcomes. The identification of molecular subsets with differential response to targeted therapies began with the identification of epidermal growth factor receptor mutated tumors in subsets of non-small cell lung cancer (NSCLC). Emboldened by unprecedented response rates to kinase inhibitors seen in that subset, the oncologic community searched for other molecular subsets featuring oncogene addiction. An early result of this search was the discovery of NSCLC driven by activating rearrangements of the anaplastic lymphoma kinase (ALK) gene. In an astoundingly brief period following the recognition of ALK-positive NSCLC, details of the biology, clinicopathologic features, development of targeted inhibitors, mechanisms of therapeutic resistance, and new generations of treatment were elucidated. This review summarizes the current understanding of the pathologic features, diagnostic approach, treatment options, resistance mechanisms, and future research areas for ALK-positive NSCLC.",
keywords = "Adenocarcinoma, Crizotinib, Oncogene addiction, Personalized medicine, Precision medicine, Targeted therapy",
author = "Tri Le and Gerber, {David E.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.semcancer.2016.08.007",
language = "English (US)",
volume = "42",
pages = "81--88",
journal = "Seminars in Cancer Biology",
issn = "1044-579X",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - ALK alterations and inhibition in lung cancer

AU - Le, Tri

AU - Gerber, David E.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - The advent of precision medicine in non-small cell lung cancer has remarkably altered the direction of research and improved clinical outcomes. The identification of molecular subsets with differential response to targeted therapies began with the identification of epidermal growth factor receptor mutated tumors in subsets of non-small cell lung cancer (NSCLC). Emboldened by unprecedented response rates to kinase inhibitors seen in that subset, the oncologic community searched for other molecular subsets featuring oncogene addiction. An early result of this search was the discovery of NSCLC driven by activating rearrangements of the anaplastic lymphoma kinase (ALK) gene. In an astoundingly brief period following the recognition of ALK-positive NSCLC, details of the biology, clinicopathologic features, development of targeted inhibitors, mechanisms of therapeutic resistance, and new generations of treatment were elucidated. This review summarizes the current understanding of the pathologic features, diagnostic approach, treatment options, resistance mechanisms, and future research areas for ALK-positive NSCLC.

AB - The advent of precision medicine in non-small cell lung cancer has remarkably altered the direction of research and improved clinical outcomes. The identification of molecular subsets with differential response to targeted therapies began with the identification of epidermal growth factor receptor mutated tumors in subsets of non-small cell lung cancer (NSCLC). Emboldened by unprecedented response rates to kinase inhibitors seen in that subset, the oncologic community searched for other molecular subsets featuring oncogene addiction. An early result of this search was the discovery of NSCLC driven by activating rearrangements of the anaplastic lymphoma kinase (ALK) gene. In an astoundingly brief period following the recognition of ALK-positive NSCLC, details of the biology, clinicopathologic features, development of targeted inhibitors, mechanisms of therapeutic resistance, and new generations of treatment were elucidated. This review summarizes the current understanding of the pathologic features, diagnostic approach, treatment options, resistance mechanisms, and future research areas for ALK-positive NSCLC.

KW - Adenocarcinoma

KW - Crizotinib

KW - Oncogene addiction

KW - Personalized medicine

KW - Precision medicine

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85011024103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011024103&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2016.08.007

DO - 10.1016/j.semcancer.2016.08.007

M3 - Review article

C2 - 27637426

AN - SCOPUS:85011024103

VL - 42

SP - 81

EP - 88

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

SN - 1044-579X

ER -